Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Neoplasm progression
ADR ID BADD_A05861
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.02      Neoplasms unspecified malignancy and site unspecified NEC
16.16.02.005      Neoplasm progression
Description Not Available
MedDRA Code 10061309
MeSH ID Not Available
ADR Severity Grade (FAERS) Not Available
ADR Severity Grade (CTCAE) Not Available
Synonym
Neoplasm progression NOS | Tumor progression | Tumour progression | Neoplasm progression | Tumour enlargement | Tumor enlargement
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01195Irinotecan0.001836%
BADD_D01197Iron0.000453%
BADD_D01248Lapatinib0.000280%
BADD_D01253Lenalidomide--
BADD_D01257Letrozole0.002239%
BADD_D01258Leucovorin0.007683%
BADD_D01260Leuprolide acetate--
BADD_D01265Levetiracetam--
BADD_D01313Lomustine0.000246%
BADD_D01601Olaparib0.000728%
BADD_D01633Oxaliplatin--
BADD_D01653Paclitaxel--
BADD_D01654Palbociclib0.384989%
BADD_D01687Pazopanib0.003156%
BADD_D01701Pemetrexed0.000672%
BADD_D01786Pixantrone--
BADD_D01799Ponatinib0.004085%
BADD_D01846Procarbazine0.000414%
BADD_D01922Regorafenib--
BADD_D02058Sorafenib--
BADD_D02097Sulindac0.000700%
BADD_D02100Sunitinib0.060632%
BADD_D02111Tamoxifen0.000238%
BADD_D02150Temozolomide0.003056%
BADD_D02217Tigecycline0.000049%
BADD_D02246Tolvaptan0.000204%
BADD_D02248Topotecan0.000302%
BADD_D02334Vandetanib0.000168%
BADD_D02344Vemurafenib--
BADD_D02360Vincristine0.001556%
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages